1. A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity;Adjei;Cancer Res,2000
2. Phase 1 and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors;Eckhardt;J Clin Oncol,1999
3. ZD1839, an oral epidermal growth factor receptor tyrosine kinase inhibitor: First phase I, pharmacokinetic results in patients;Hammond;Proc Am Soc Clin Oncol,1999
4. LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS);Grindley;Proc Am Assoc Cancer Res,1992
5. Antimetabolites;Schilsky,1992